GSK plc logo
GSKGSK plc

Income Statement

Revenue, expenses, and profitability analysis

Quarterly Income Statement (USD)

Quarterly ReportTTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
12/31/2024
09/30/2024
06/30/2024
44.136B10.084B11.596B11.491B10.966B9.708B10.155B10.715B9.967B
Cost of Goods Sold
12.062B2.478B3.575B3.036B2.973B2.502B3.202B3.206B2.683B
32.074B7.605B8.021B8.455B7.993B7.206B6.954B7.509B7.284B
75.4%75.4%69.2%73.6%72.9%74.2%68.5%70.1%73.1%
Total Operating Expenses
20.753B4.575B5.994B4.969B5.215B4.344B6.083B7.257B5.203B
10.448B2.236B3.162B2.271B2.779B1.888B2.541B1.951B1.867B
12.300B2.801B3.551B3.010B2.938B2.674B3.332B5.082B3.116B
11.321B3.031B2.026B3.486B2.778B2.862B870.786M252.763M2.081B
30.1%30.1%17.5%30.3%25.3%29.5%8.6%2.4%20.9%
10.005B2.834B1.278B3.302B2.591B2.723B704.386M85.592M1.890B
Interest Income
132.690M29.078M34.955M68.656M69.751M-63.808M42.796M30.340M
932.030M220.731M234.124M224.521M252.654M209.254M180.163M208.630M219.967M
Other Income/Expense
-1.316B-196.939M-748.120M-184.188M-186.744M-139.503M-166.400M-167.171M-190.891M
7.839B2.296B855.763M2.706B1.981B2.098B517.968M-77.567M1.483B
1.454B403.131M300.055M419.465M330.922M434.008M77.570M-1.337M241.458M
22.8%22.8%7.4%23.6%18.1%21.6%5.1%-0.7%14.9%
15.570B3.643B3.080B4.478B4.369B3.925B1.386B1.525B2.889B
36.1%36.1%26.6%39.0%39.8%40.4%13.7%14.2%29.0%
4.249B611.966M1.053B992.197M1.591B1.063B515.466M1.272B807.811M
4.601.141.131.340.991.030.25-0.040.73
4.521.141.101.320.961.010.25-0.040.71
2.011B2.011B1.005B2.017B2.031B2.044B2.041B2.040B2.039B
2.037B2.037B1.022B2.051B2.055B2.068B2.072B2.040B2.061B

Annual Income Statement (USD)

Annual Report
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
43.955B39.255B38.587B35.440B33.419B33.258B44.725B39.263B
Cost of Goods Sold
12.133B11.320B10.898B11.547B11.046B10.828B15.719B13.046B
31.822B27.935B27.690B23.893B22.373B22.430B29.006B26.217B
72.4%71.2%71.8%67.4%66.9%67.4%64.9%66.8%
Total Operating Expenses
20.603B22.904B19.108B16.119B16.477B14.265B19.783B19.232B
10.125B8.008B7.918B6.633B6.792B6.545B6.053B4.959B
12.228B13.781B11.941B10.118B9.567B10.156B15.108B12.631B
11.219B5.031B8.582B7.775B5.896B8.165B9.223B6.985B
25.5%12.8%22.2%21.9%17.6%24.6%20.6%17.8%
9.958B4.350B7.715B6.802B4.870B7.060B8.243B6.115B
Interest Income
75.350M84.316M50.893M77.669M37.890M60.087M129.852M99.155M
924.386M822.718M986.056M1.034B1.061B1.218B1.208B947.325M
Other Income/Expense
-1.261B-680.615M-866.457M-972.899M-1.026B-1.105B-980.515M-870.081M
7.691B3.222B6.270B18.075B5.934B7.851B6.155B4.615B
1.496B658.094M961.881M854.459M112.318M91.496M1.263B960.528M
17.5%8.2%16.2%51.0%17.8%23.6%13.8%11.8%
14.333B8.222B11.501B10.370B8.768B10.964B12.033B9.349B
32.6%20.9%29.8%29.3%26.2%33.0%26.9%23.8%
3.114B3.192B2.919B2.595B2.872B2.800B2.809B2.364B
7.591.583.108.993.713.933.102.34
7.481.553.058.853.653.913.072.32
1.013B2.038B2.026B2.013B1.601B1.990B1.979B1.966B
1.029B2.071B2.055B2.042B1.621B2.015B2.006B1.988B

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About GSK plc

GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.

Brentford
68,629 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Luke Victor Miels